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Abstract
Background: The Temperament and Character Inventory (TCI) is a psychological test that is frequently used to
assess personality traits. Many studies have shown the potential of the inventory to predict the treatment response of
patients with major depressive disorder (MDD). Previously, we showed the association between 10 items of the TCI
and the treatment response. In the present study, we reanalyzed the 10 items and aimed to provide cut-off values.
Methods: This work is a secondary analysis of previously published work. Seventy-three patients were enrolled in the
previously done study. Participants were treated with 10–40 mg/day of paroxetine for six weeks, and then the
participants completed the TCI. The Montgomery-Asberg Depression Rating Scale (MADRS) was used to evaluate
depression. The participants were divided into two groups (responders and non-responders). Using chi-squared
tests, we reanalyzed the 10 items that had the strongest association with the treatment response in the previous
study. We rated the answers to each item associated with the treatment response as a “1”, and the answers
associated with a non-response were rated as a “0”. We calculated predictive scores using 10 models. Each
model consisted of 1–10 scores of the best 1–10 items. We defined cut-off values for predicting treatment
responses using a receiver operating characteristic (ROC) curve analysis.
Results: Ranked by the strength of the association with the treatment response, items 174, 137, 70, 237, 106,
191, 34, 232, 161, and 215 of the TCI significantly predicted treatment responses. All predictive scores from
models 1 to 10 significantly predicted treatment responses. The predictive score threshold of model 7 was 3/4, with an
area under the curve of 0.825, and this model showed the highest odds and likelihood ratios (19.3 and 8.86, respectively).
Conclusions: We might predict the treatment response of patients with MDD using TCI predictive scoring,
including items 174, 137, 70, 237, 106, 191, and 34 and a cut-off value of 3/4.
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Background
The Temperament and Character Inventory (TCI) is
frequently used to assess personality traits [1]. The re-
sults of this questionnaire are summarized in seven
dimensions; four dimensions are related to tempera-
ment (novelty seeking [NS], harm avoidance [HA], re-
ward dependence [RD], and persistence [P]), and three
dimensions are related to character (self-directedness
[SD], cooperativeness [C], and self-transcendence [ST]).
Many studies have shown an association between these
TCI dimension values and disorders or certain mental
conditions. Mitsui et al. investigated the association be-
tween suicide and the tendency of the TCI of university
students and showed higher HA scores in subjects who
committed suicide [2]. In another study, high NS and
HA scores were reported to be risk factors for affective
disorders [3].
Some studies reported the negative influence of per-
sonality disorders or personality dysfunction on the
outcome of the treatment for the patients with depres-
sion. There were the association between comorbid or
pre-existing personality disorders or personality dys-
function and poor response to treatment for depression
[4, 5]. Additionally, the relationships between major
depressive disorder (MDD) or depression and personal-
ity traits evaluated using TCI scores have been exam-
ined in many previous studies. High HA and low SD
have been associated with depressed mood [6–14]. Fur-
thermore, many studies have suggested that high HA
scores are strongly associated with a depressive state or
MDD on the TCI subscales [6, 9–14]. Therefore, MDD
or a depressive state may be related to the personality
traits that depend on higher HA.
Changes in TCI scores after treatment of patients with
MDD were reported in previous studies [11, 15–18].
The results of these studies showed a significant de-
crease in HA scores after treatment or in the patients
who showed a response to the treatment, and some of
these studies reported changes in the SD, C, and ST
scores [15–17]. In the study of Abrams et al., the inverse
correlation between HA and improvement after treat-
ment [18].
Thus, TCI dimensions are significantly correlated
with MDD and depressive symptoms. Specific dimen-
sions of the TCI may allow us to predict treatment re-
sponses in patients with MDD, which may prove
beneficial in clinical settings. However, the TCI consists
of 240 items, causing a potential burden to patients.
We previously reported that some TCI items showed
significant associations with paroxetine treatment re-
sponses in patients with MDD. It is also possible to
predict treatment responses in patients with MDD
using only 10 items (items 34, 70, 106, 137, 161, 174,
191, 215, 232 and 237) [19].
Our suggestion was novel, and predicting this response
was difficult because we did not provide cut-off values
with regard to how many answers associated with the re-
sponses that MDD patients had. In the present study, we
reanalyzed the 10 items and aimed to provide these cut-
off values for predicting treatment responses.
Methods
Participants
This work is a secondary analysis of previously published
work.
Between December 2004 and September 2008, male and
female patients between 19 and 72 years of age with a
diagnosis of MDD, according to the Diagnostic and Statis-
tical Manual (DSM)-IV, were recruited for participation in
the previously done study. Participants were recruited
from the Hospital of the Hirosaki University School of
Medicine, Hirosaki-Aiseikai Hospital, Kuroishi-Akebono
Hospital, and Odate Municipal General Hospital. Partici-
pants were included in the study if they scored higher
than a 20 on the Montgomery Asberg Depression Rating
Scale (MADRS) [20].
Of the 106 patients who were initially enrolled, 73
completed the study (25 males and 48 females). Thirty-
three patients withdrew from the study, with 17 failing
to complete the TCI questionnaire and 16 experiencing
severe side effects from the medication. One patient in-
cluded in the number of patients who failed to complete
the TCI experienced a manic phase, and her diagnosis
was changed to bipolar disorder. The mean ± standard
deviation ages of completers, responders of completers,
non-responders of completers, patients who withdrew
because of failing to complete the TCI questionnaire,
and patients who withdrew because of severe side effects
were 45.6 ± 14.1 years, 46.9 ± 13.1 years, 44.1 ± 15.4 years,
50.7 ± 14.6 years, and 44.3 ± 17.1 years, respectively.
Approval was obtained from the Ethics Committee of
the Hirosaki University School of Medicine prior to the
study. The participants provided written informed con-
sent after receiving a full description of the study.
Measures
The MADRS consists of 10 items that are scored from
0 to 6. We excluded patients who had taken medica-
tions, including psychotropic agents, within the month
prior to the start of the study. We also excluded indi-
viduals with clinically significant abnormal laboratory
or electrocardiographic findings, histories of mental
illness other than depression (e.g., bipolar disorder,
mania, schizophrenia, epilepsy, alcohol/drug abuse, per-
sonality disorder), or clinically significant organic or
neurological diseases.
The Udvalg for Kliniske Undersogelser (UKU) is a
comprehensive scale that assesses the side effects of
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psychotropic drugs and consists of 48 items rated from
0 to 3 according to the presence or severity of the side
effects [21]. A UKU score of 1 was defined as mild side
effects, a UKU score of 2 was defined as moderate side
effects, and a UKU of 3 was defined as severe side
effects.
The 240-item Japanese version of the TCI was used at
the beginning of the study. The TCI consisted of yes-no
questionnaires and the 7 dimensions described above.
The reliability and validity of this instrument had been
previously established [22]. Kijima et al. reported the in-
ternal consistency of TCI among Japanese subjects as
0.64–0.85 [23].
Protocol
A dose of 20 mg/day of paroxetine (Paxil, GlaxoSmithK-
line, Tokyo, Japan) was administered at 8 PM each day
during the first week; the dose was then increased to
40 mg/day and administered from the second week to
the sixth week. Blood samples were collected during
treatment weeks 1, 2, and 6. Clinical symptoms were
evaluated using the MADRS and the UKU side effect
rating scale during treatment weeks 0, 1, 2, 4, and 6. If
mild side effects (a UKU score of 1) were observed, the
dose of paroxetine was maintained [21]. The dose was
decreased if moderate side effects were observed (a
UKU score of 2), and paroxetine administration was
discontinued if severe side effects were observed (a
UKU score of 3). The only other drugs administered
during the study were diazepam (2–5 mg/day) for anx-
iety, brotizolam (0.25 mg/day) for insomnia, and senno-
side (12–48 mg/day) for constipation.
Data analysis and statistics
We defined responders as patients with MADRS im-
provements of > 50 % from baseline at week 6. A t-test
and chi-square test were performed to compare demo-
graphic data and MADRS scores between the responders
and non-responders.
In our previous study, we performed a chi-square test
to evaluate the association between the results of the
questionnaire and the responder rate for each of the 240
TCI items. We then identified the 10 items with the
strongest associations with treatment response (items
34, 70, 106, 137, 161, 174, 191, 215, 232, and 237) [19].
In the present study, we reanalyzed the 10 items using a
chi-square test. Answers with either a yes or no were as-
sociated with a non-response.
We rated the answers to each item associated with a
response as a “1”, and those associated with a non-
response were rated as a “0”. We constructed 10 models
consisting of the TCI items. Each model consisted of
scores from the 1 to 10 TCI items shown above. Models
1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 consisted of scores from
the items with the best, best and second, best to third,
best to fourth, best to fifth, best to sixth, best to seventh,
best to eighth, best to ninth, and best to tenth strongest
association with treatment response, respectively. We
defined the scores of each model as predictive scores.
We compared the predictive scores between responders
and non-responders using a t-test.
We used a receiver operating characteristic (ROC)
curve to analyze the scores of each model to determine
cut-off points using those that yielded the highest com-
bined sensitivity and specificity for distinguishing re-
sponders and non-responders.
A p-value of < 0.05 was considered statistically signifi-
cant. All analyses were performed using SPSS 22 for
Windows (SPSS Japan Inc., Tokyo, Japan) and StatFlex
version 6 (Artech Co, Ltd, Tokyo, Japan).
Results
Demographic and clinical characteristics
Table 1 shows the demographic and clinical characteris-
tics of the patients, responders, and non-responders.
The patients included 25 males and 48 females. The re-
sponders included 14 males and 28 females, and the
non-responders included 11 males and 20 females. No
significant difference in baseline MADRS score was
found between the responders and non-responders. No
significant differences in TCI dimensions were found,
except for C.
TCI items predicted the response and the predictive
score models
The upper part of Table 2 shows the results of the chi-
square tests to distinguish responders from non-
responders. The TCI items are ordered by the strength
of their relationship with treatment response. All 10
items showed significant differences. The lower part of
Table 2 shows predictive score comparisons between
responders and non-responders. All predictive scores
were significant (Additional file 1).
ROC curve analysis
Figure 1 shows the ROC curves for the predictive scores
of the treatment response for models 1–10. The thresh-
olds of the predictive scores of models 1–10 that gave
maximal sensitivity and specificity for treatment re-
sponse were 0/1, 0/1, 1/2, 2/3, 2/3, 2/3, 3/4, 3/4, 4/5 and
4/5. The sensitivity and specificity of the predictive
scores for models 1–10 were 81.0 and 45.2 %; 88.1 and
38.7 %; 61.9 and 67.7 %; 54.8 and 90.3 %; 59.5 and
87.1 %; 61.9 and 74.2 %; 57.1 and 93.5 %; 81.0 and
67.7 %; 69.0 and 87.1 %; and 71.4 and 83.9 %. Table 3
shows the ROC curve analysis summary. The predictive
score threshold of model 7 showed the highest odds and
likelihood ratios (19.3 and 8.86, respectively).
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Discussion
The present study demonstrated that the predictive
scores of models including TCI items associated with
treatment responses are able to predict treatment re-
sponse. Cut-off values were also established that could
distinguish responders from non-responders. This is the
first study to utilize the TCI items associated with treat-
ment responses that were reported previously [19].
In the present study, the areas under curve (AUC) of
models 5, 7, 8, 9, and 10 were over 0.800, with the AUC
of model 10 being the highest (0.860). However, the
pairwise analysis to compare the AUCs of the above-
mentioned models demonstrated no significant differ-
ences. Model 7 showed the highest odds and likelihood
ratios. To predict treatment responses in patients with
MDD without overburdening patients, we should
accept model 7 as the predictive model (including items
174, 137, 70, 237, 106, 191 and 34) and use a cut-off
value of 3/4 for the predictive score.
Several previous studies have evaluated the ability of
different instruments to predict treatment response in
patients with MDD [24–26]. Kampman et al. reported
that baseline and endpoint HA scores were correlated
in patients with MDD using selective serotonin re-
uptake inhibitors (SSRIs) [24]. Furthermore, endpoint
HA scores were shown to be associated with endpoint
MADRS scores. A study using the Minnesota Multi-
phasic Personality Inventory-2 showed that the Social
Introversion score was significantly associated with
SSRI responses in patients with MDD [25]. In a study
using the Five-Factor Model, Quilty et al. found that
these personality traits were associated with treatment
responses [26]. In the present and previous studies, we
constructed a short version of the TCI to predict the
treatment responses of patients with MDD using parox-
etine. The short version of the TCI might be useful for
predicting the treatment response of patients with
MDD, but we need further study to investigate the per-
sonality traits of patients with MDD using the short
version of the TCI in clinical settings.
Several previous studies have reported that HA and
SD are closely related to depression and treatment re-
sponses in patients with MDD [6–14]. However, the in-
dependent variables that predicted treatment response
according to logistic regression models 1–10 in the pre-
vious study included no HA items and just one item
from the SD dimension [19]. The HA and SD scores
were significantly associated with MDD. However, the
use of different items within these dimensions may
have counteracted the predictive effects of other items.
In the present study, there were relatively higher dropout
rate in the participants. The compliance of medication
might be associated with character or temperament of the
patients. The results of present study might reflect the







Age 46.9 ± 13.1 44.1 ± 15.4 0.441
Sex (male:female) 14:28 11:20 0.522
Disease duration (months) 10.3 ± 17.0 16.6 ± 23.1 0.248
MADRS score
0W 40.0 ± 8.6 39.2 ± 11.2 0.718
6W 5.7 ± 5.3 29.3 ± 9.5 0.000**
TCI dimensions
NS 17.8 ± 4.1 16.6 ± 5.2 0.276
HA 27.0 ± 4.1 28.4 ± 3.9 0.136
RD 13.9 ± 3.6 13.7 ± 2.9 0.822
P 3.8 ± 1.7 4.3 ± 1.9 0.222
SD 21.2 ± 6.6 19.3 ± 6.0 0.199
C 27.8 ± 3.9 25.0 ± 5.7 0.026*
ST 11.8 ± 5.2 9.6 ± 4.8 0.065
NS novelty seeking, HA harm avoidance, RD reward dependence, P persistence,
SD self-directedness, C cooperativeness, ST self-transcendence
*; p < 0.05, **; p < 0.01
Table 2 TCI items predicted the response and the predictive






TCI items (yes:no) 174 (NS) 35:7 17:14 0.008**
137 (C) 19:23 5:26 0.008**
70a (NS) 19:23 23:8 0.012*
237a (NS) 10:32 16:15 0.014*
106a (SD) 28:14 28:3 0.016*
191 (NS) 19:23 6:25 0.019*
34a (NS) 11:31 16:15 0.024*
232 (ST) 35:7 19:12 0.032*
161 (C) 16:26 5:26 0.035*
215 (ST) 14:28 4:27 0.040*
Predictive score model 1 0.8 ± 0.4 0.5 ± 0.5 0.021*
model 2 1.3 ± 0.7 0.7 ± 0.6 0.000**
model 3 1.8 ± 0.9 1.0 ± 0.8 0.000**
model 4 2.6 ± 1.0 1.5 ± 0.9 0.000**
model 5 2.9 ± 1.3 1.5 ± 0.9 0.000**
model 6 3.4 ± 1.4 1.7 ± 1.0 0.000**
model 7 4.1 ± 1.6 2.2 ± 1.0 0.000**
model 8 4.9 ± 1.7 2.8 ± 1.2 0.000**
model 9 5.3 ± 1.7 3.0 ± 1.2 0.000**
model 10 5.6 ± 1.9 3.1 ± 1.3 0.000**
NS novelty seeking, SD self-directedness, C cooperativeness, ST self-transcendence
a; “no” answers were associated with the response, *; p < 0.05, **; p < 0.01
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characteristics of the specific patients who continued tak-
ing their medicines.
Ten TCI items were selected for inclusion in models
1–10 to calculate the predictive scores. The dimension
containing the largest number of independent variables
was NS. However, few studies have reported an associ-
ation between the NS score and treatment response in
patients with MDD. The finding that higher NS scores
predict treatment response has already been discussed in
a previous study [19]. Tome et al. reported that patients
Fig. 1 Receiver operating characteristic curves. a-j show the curves of model 1–10, respectively
Table 3 The results of receiver operating characteristic curve analysis
Cut off AUC Sensitivity (%) Specificity (%) PPV (%) NPV (%) Odds ratio Likelihood ratio Accuracy (%)
model 1 0/1 0.631 81.0 45.2 66.7 63.6 3.5 1.48 65.8
2 0/1 0.708 88.1 38.7 66.1 70.6 4.7 1.44 67.1
3 1/2 0.738 61.9 67.7 72.2 56.8 3.4 1.92 64.4
4 2/3 0.788 54.8 90.3 88.5 59.6 11.3 5.66 69.9
5 2/3 0.801 59.5 87.1 86.2 61.4 9.9 4.61 71.2
6 2/3 0.799 61.9 74.2 76.5 59.0 4.7 2.40 67.1
7 3/4 0.825 57.1 93.5 92.3 61.7 19.3 8.86 72.6
8 3/4 0.836 81.0 67.7 77.3 72.4 8.9 2.51 75.3
9 4/5 0.858 69.0 87.1 87.9 67.5 15.1 5.35 76.7
10 4/5 0.860 71.4 83.9 85.7 68.4 13.0 4.43 75.7
AUC area under curve, PPV positive predictive value, NPV positive predictive value
Tomita et al. BMC Psychiatry  (2016) 16:290 Page 5 of 7
with MDD who had higher NS scores exhibited better
treatment responses [27]. Genetic and biological studies
related to NS scores have also been conducted. One
study investigated a serotonin transporter promoter
polymorphism (SERTPR) and reported a significant as-
sociation between lower NS scores and homozygosity
for the short allele [28]. A study investigating tryptophan
hydroxylase (TPH1) genotypes and the TCI showed
that the TPH1 A allele was associated with higher
scores on the NS1 and NS2 subscales. Nakao et al.
found an association between NS scores and the power
of slow neuronal oscillations during the resting state
using near-infrared spectroscopy [29]. Genetic or bio-
logical factors may influence the ability to predict treat-
ment responses based on NS items.
None of the 10 items with the most significant associ-
ations with treatment response belonged to the HA di-
mension. The list of the 20 best items included only
one HA item (Table 2) [19]. In contrast, the NS dimen-
sion contained the largest number of items in both the
top 10 and top 20 lists. In a study using healthy student
volunteers, Peirson et al. demonstrated that 5-HT2 re-
ceptor sensitivity was positively associated with HA,
negatively associated with SD, and not correlated with
NS [30]. The biological mechanism underlying the abil-
ity of NS to predict treatment response might be unre-
lated to serotonin receptor sensitivity. Some studies
have reported associations between dopaminergic func-
tion and the NS dimension [31–33]. In a study using
positron emission tomography, Suhara et al. demon-
strated an association between NS scores and dopamine
D2 receptor-binding potential [32]. Lee et al. found an
association between NS and heterozygosity for the
short allele of the dopamine D4 receptor gene in a fe-
male sample [33]. The ability of NS to significantly pre-
dict treatment responses in patients with MDD might
involve a dopaminergic mechanism, and its association
with the responders might not be associated with par-
oxetine or serotonergic functions.
The present study has some limitations. First, we ex-
cluded the patients with depression due to personality
disorders or other disorders (e.g., bipolar disorder) and
used only a single antidepressant, paroxetine, and did
not evaluate the influence of additional drugs that were
used, such as diazepam, brotizolam, and sennoside. The
cut-off values might not apply to the patients with de-
pression due to disorders except for MDD. According to
Cloninger’s theory, some TCI dimensions are associated
with neurotransmitters, including dopamine, serotonin,
and noradrenaline [31]. Paroxetine and SSRIs mainly
act on serotonergic mechanisms. Other classes of anti-
depressants act on other mechanisms, potentially chan-
ging the results. Other models or TCI items are needed
to predict their effectiveness for patients with MDD.
Further studies including other antidepressants would
help to construct TCI predictive models for various
treatment responses. Additional drugs might contribute
to completion or responsivity to the treatment of the
patients who used additional drugs. Second, the present
study might have a selection bias. The results and dis-
cussion lack information on the 17 patients who did
not complete the TCI. These participants' characters or
temperaments might be different from those who com-
pleted the TCI. We should investigate whether the pre-
dictive model in the present study might predict the
treatment responses of patients who did and did not
complete the TCI. Third, TCI scores show only trait
states of the patients with MDD, and we can evaluate
the scores of items shown in the present study as im-
portant only by using TCI. TCI traits are only one of
the factors associated with response to treatment. We
cannot evaluate the important items shown in the
present study by the impression of the patients in the
clinical settings but we have to use TCI to evaluate the
important items.
Conclusions
We investigated and constructed a predictive model for
MDD and treatment response that included TCI items
associated with treatment response, and we determined
the cut-off values of predictive scores. We might predict
the treatment responses of patients with MDD using the
predictive scores of items 174, 137, 70, 237, 106, 191
and 34, with a cut-off value of 3/4.
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